EVOQ's NanoDisc technology is designed to enable lymph-targeted delivery of disease-specific antigens and has the potential to change the paradigm for the treatment of autoimmune diseases.
Under the agreement, Gilead and EVOQ will collaborate on preclinical development.
Gilead has the option to exclusively license rights to EVOQ's NanoDisc technology to pursue product candidates for RA and lupus indications and will be responsible for clinical development and commercialization.
Beginning in the first quarter of 2022, consistent with recent industry communications from the US Securities and Exchange Commission, Gilead no longer excludes acquired IPR&D expenses from its non-GAAP financial measures.
The transaction with EVOQ is expected to have a de minimis financial impact on Gilead's GAAP and non-GAAP EPS.
Under the terms of the agreement, EVOQ could potentially receive up to USD 658.5m total in upfront, option exercise and milestone payments across all programs, as well as tiered royalties on product sales.
EVOQ Therapeutics is advancing a pipeline of disease-specific immune modulators to treat patients afflicted with autoimmune diseases.
EVOQ's technology platform utilizes a proprietary NanoDisc that has been optimized to deliver antigens to restore immune tolerance.
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.
The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, cancer, and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
BenevolentAI and AstraZeneca collaboration leads to novel target for lupus
UCB announces results from three studies supporting the value of CIMZIA(R) (certolizumab pegol)
Henlius and Organon report success of HLX14 Phase 3 study
Nobelpharma's inhaled use of Leukine receives Japanese regulatory approval to treat aPAP
RemeGen's Telitacicept receives US FDA Fast Track Designation
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
AstraZeneca announces US approval for Ultomiris for NMOSD treatment
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis